A phase II study of AN2-502998
Latest Information Update: 15 Dec 2025
At a glance
- Drugs AN2 502998 (Primary)
- Indications Chagas disease
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 12 Nov 2025 According to AN2 Therapeutics media release, initiation of this Phase 2 proof-of-concept study in patients with chronic Chagas disease in 2026, depending upon the outcome and timing of completion of the Phase 1 study.
- 13 Aug 2025 New trial record
- 12 Aug 2025 According to AN2 Therapeutics media release, data expected in 2027.